Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE
China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...
BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...
Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products
China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...
Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...
Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...
Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination
Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...
SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round
Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...
Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa
Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease
France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD)...
Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...
Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products
US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...
CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials
China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...
Bio-heart Launches Iberis Renal Ablation System at OCC 2025
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...
BioAge Labs Partners with JiKang for APJ Agonist Nanobody License
US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...